Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma.
Pretargeted radioimmunotherapy (PRIT) decreases the amount of time that radioactivity non-selectively circulates. Our PRIT approach is a multi-step method in which a monoclonal antibody is used to target streptavidin to a tumor-associated antigen and biotin is then used to target 90Y to the streptavidin. A genetically engineered antibody streptavidin fusion construct was used to target tumor in a patient with non-Hodgkin's lymphoma. Impressive localization of 90Y to known and previously unknown areas of adenopathy was observed, thus demonstrating that a genetically engineered fusion protein can selectively target lymphoma cells as part of a clinically meaningful PRIT strategy.
Weiden
Paul L
PL
Virginia Mason Medical Center, 1100 Ninth Avenue, Seattle, WA 98101, USA. pweiden@dendreon.com
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D001710:Biotin; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D007205:Indium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000379:methods*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D012211:Rhenium / Q000008:administration & dosage / Q000627:therapeutic use; D019809:Streptavidin; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D018796:Immunoconjugates; D007205:Indium Radioisotopes; D011993:Recombinant Fusion Proteins; D015021:Yttrium Radioisotopes; D001710:Biotin; D012211:Rhenium; D019809:Streptavidin